Towards a classification of biomarkers of neuropsychiatric disease: From encompass to compass

Molecular Psychiatry

Volumn 20, Issue 2, 2015, Pages 152-153

  Davis, J ^a   Maes, M ^a   Andreazza, A ^b   McGrath, J J ^c,d   Tye, S J ^a,e   Berk, M ^a,f,g,h  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d QUEENSLAND CENTRE FOR MENTAL HEALTH RESEARCH   (Australia)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; INTERLEUKIN 10; INTERLEUKIN 6; NEUROTROPHIN 3; TAU PROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

BIPOLAR DISORDER; DEPRESSION; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE SEVERITY; HEALTH STATUS; HUMAN; INFLAMMATION; INTOXICATION; MANIA; MILD COGNITIVE IMPAIRMENT; NEUROSIS; OXIDATIVE STRESS; PATIENT ACUITY; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; CLASSIFICATION; MENTAL DISORDERS; METABOLISM;

BIOMARKERS; HUMANS; MENTAL DISORDERS;

EID: 84937717957     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.139     Document Type: Review

References (10)

1. Guintivano J, Arad M, Gould TD, Payne JL, Kaminsky ZA. Antenatal prediction of postpartum depression with blood DNA methylation biomarkers. Mol Psychiatry 2014; 19: 560-567.
2. Lencz T, Knowles E, Davies G, Guha S, Liewald DC, Starr JM et al. Molecular genetic evidence for overlap between general cognitive ability and risk for schizophrenia: a report from the Cognitive Genomics consorTium (COGENT). Mol Psychiatry 2014; 19: 168-174.
3. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 2012; 17: 494-502.
4. Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant'Anna M, Klamt F et al. A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol Psychiatry 2010; 15: 784-786.
5. Fernandes BS, Berk M, Turck CW, Steiner J, Goncalves CA. Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Mol Psychiatry 2014; 19: 750-751.
6. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 2010; 15: 138-145.
7. Wolkowitz OM, Mellon SH, Epel ES, Lin J, Reus VI, Rosser R et al. Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response. Mol Psychiatry 2012; 17: 164-172.
8. Rethorst CD, Toups MS, Greer TL, Nakonezny PA, Carmody TJ, Grannemann BD et al. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry 2013; 18: 1119-1124.
9. Chen CH, Lee CS, Lee MT, Ouyang WC, Chen CC, Chong MY et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med 2014; 370: 119-128.
10. Krishnadas R, Cavanagh J. Depression: an inflammatory illness?. J Neurol Neurosurg Psychiatry 2012; 83: 495-502.